“…Numerous correlative and mechanistic links of PYCR1 to cancer progression and metastasis have been reported. Many studies have shown that high PYCR1 expression is associated with tumor aggressiveness and poor patient outcomes (Alaqbi et al, 2022; Ding et al, 2017, 2020; Du et al, 2021; Li, Xu, et al, 2022; Li, Liu, et al, 2022; Liu et al, 2021; Oudaert et al, 2022; Shao et al, 2022; Shenoy et al, 2020; Weijin et al, 2019; Xiao et al, 2020; Xu et al, 2021; Zhang et al, 2021), and the knockdown of the PYCR1 gene or the inhibition of PYCR1 enzyme has been shown to inhibit tumorigenesis in cancer cell lines and animal models of cancer (Alaqbi et al, 2022; Cai et al, 2018; Christensen et al, 2020; Ding et al, 2020; Du et al, 2021; Elia et al, 2017; Gao et al, 2020; Li et al, 2023; Li, Liu, et al, 2022; Li, Xu, et al, 2022; Sang et al, 2019; Shenoy et al, 2020; Xiao et al, 2020; Xu et al, 2021; Yan et al, 2019; Zeng et al, 2017; Zhuang et al, 2019). The production of proline via PYCR1 may be an indicator of cancer stem‐like cells, which can survive chemotherapy treatments and lead to relapse in cancer patients (Sharif et al, 2019).…”